Cargando…

The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients

Different inflammation-based scores such as the neutrophil/lymphocyte ratio (NLR), the Odonera Prognostic Nutritional Index (PNI), the Glasgow Prognostic Score, the platelet/lymphocyte ratio, and the C-reactive protein/albumin ratio have been found to be significantly associated with pancreatic canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Piciucchi, Matteo, Stigliano, Serena, Archibugi, Livia, Zerboni, Giulia, Signoretti, Marianna, Barucca, Viola, Valente, Roberto, Delle Fave, Gianfranco, Capurso, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412316/
https://www.ncbi.nlm.nih.gov/pubmed/28353661
http://dx.doi.org/10.3390/ijms18040730
_version_ 1783232971624415232
author Piciucchi, Matteo
Stigliano, Serena
Archibugi, Livia
Zerboni, Giulia
Signoretti, Marianna
Barucca, Viola
Valente, Roberto
Delle Fave, Gianfranco
Capurso, Gabriele
author_facet Piciucchi, Matteo
Stigliano, Serena
Archibugi, Livia
Zerboni, Giulia
Signoretti, Marianna
Barucca, Viola
Valente, Roberto
Delle Fave, Gianfranco
Capurso, Gabriele
author_sort Piciucchi, Matteo
collection PubMed
description Different inflammation-based scores such as the neutrophil/lymphocyte ratio (NLR), the Odonera Prognostic Nutritional Index (PNI), the Glasgow Prognostic Score, the platelet/lymphocyte ratio, and the C-reactive protein/albumin ratio have been found to be significantly associated with pancreatic cancer (PDAC) prognosis. However, most studies have investigated patients undergoing surgery, and few of them have compared these scores. We aimed at evaluating the association between inflammatory-based scores and PDAC prognosis. In a single center cohort study, inflammatory-based scores were assessed at diagnosis and their prognostic relevance as well as that of clinic-pathological variables were evaluated through multiple logistic regression and survival probability analysis. In 206 patients, age, male sex, tumor size, presence of distant metastasis, access to chemotherapy, and an NLR > 5 but not other scores were associated with overall survival (OS) at multivariate analysis. Patients with an NLR < 5 had a median survival of 12 months compared to 4 months in those with an NLR > 5. In the 81 patients with distant metastasis at diagnosis, an NLR > 5 resulted in the only variable significantly associated with survival. Among patients with metastatic disease who received chemotherapy, the median survival was 3 months in patients with an NLR > 5 and 7 months in those with an NLR < 5. The NLR might drive therapeutic options in PDAC patients, especially in the setting of metastatic disease.
format Online
Article
Text
id pubmed-5412316
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54123162017-05-05 The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients Piciucchi, Matteo Stigliano, Serena Archibugi, Livia Zerboni, Giulia Signoretti, Marianna Barucca, Viola Valente, Roberto Delle Fave, Gianfranco Capurso, Gabriele Int J Mol Sci Article Different inflammation-based scores such as the neutrophil/lymphocyte ratio (NLR), the Odonera Prognostic Nutritional Index (PNI), the Glasgow Prognostic Score, the platelet/lymphocyte ratio, and the C-reactive protein/albumin ratio have been found to be significantly associated with pancreatic cancer (PDAC) prognosis. However, most studies have investigated patients undergoing surgery, and few of them have compared these scores. We aimed at evaluating the association between inflammatory-based scores and PDAC prognosis. In a single center cohort study, inflammatory-based scores were assessed at diagnosis and their prognostic relevance as well as that of clinic-pathological variables were evaluated through multiple logistic regression and survival probability analysis. In 206 patients, age, male sex, tumor size, presence of distant metastasis, access to chemotherapy, and an NLR > 5 but not other scores were associated with overall survival (OS) at multivariate analysis. Patients with an NLR < 5 had a median survival of 12 months compared to 4 months in those with an NLR > 5. In the 81 patients with distant metastasis at diagnosis, an NLR > 5 resulted in the only variable significantly associated with survival. Among patients with metastatic disease who received chemotherapy, the median survival was 3 months in patients with an NLR > 5 and 7 months in those with an NLR < 5. The NLR might drive therapeutic options in PDAC patients, especially in the setting of metastatic disease. MDPI 2017-03-29 /pmc/articles/PMC5412316/ /pubmed/28353661 http://dx.doi.org/10.3390/ijms18040730 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Piciucchi, Matteo
Stigliano, Serena
Archibugi, Livia
Zerboni, Giulia
Signoretti, Marianna
Barucca, Viola
Valente, Roberto
Delle Fave, Gianfranco
Capurso, Gabriele
The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
title The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
title_full The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
title_fullStr The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
title_full_unstemmed The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
title_short The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
title_sort neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412316/
https://www.ncbi.nlm.nih.gov/pubmed/28353661
http://dx.doi.org/10.3390/ijms18040730
work_keys_str_mv AT piciucchimatteo theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT stiglianoserena theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT archibugilivia theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT zerbonigiulia theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT signorettimarianna theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT baruccaviola theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT valenteroberto theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT dellefavegianfranco theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT capursogabriele theneutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT piciucchimatteo neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT stiglianoserena neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT archibugilivia neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT zerbonigiulia neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT signorettimarianna neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT baruccaviola neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT valenteroberto neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT dellefavegianfranco neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients
AT capursogabriele neutrophillymphocyteratioatdiagnosisissignificantlyassociatedwithsurvivalinmetastaticpancreaticcancerpatients